Long-term Extension, Multicentre, Multi-national Study to Evaluate the Safety and Tolerability of Oral BAY63-2521 (1mg, 1.5 mg, 2.0 mg, 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH)

Trial Profile

Long-term Extension, Multicentre, Multi-national Study to Evaluate the Safety and Tolerability of Oral BAY63-2521 (1mg, 1.5 mg, 2.0 mg, 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Nov 2017

At a glance

  • Drugs Riociguat (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Adverse reactions; Registrational
  • Acronyms PATENT-2
  • Sponsors Bayer; Bayer HealthCare
  • Most Recent Events

    • 11 Nov 2017 Results of post hoc analysis from PATENT-1 and PATENT-2, were published in the Journal of Heart and Lung Transplantation.
    • 03 May 2017 Planned End Date changed from 1 Apr 2019 to 31 Dec 2018.
    • 03 May 2017 Planned primary completion date changed from 1 Mar 2019 to 31 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top